Single-cell editing platform
Technology Platform Overview
Single-Cell Gene Editing Platform: One-Step Knockout Cloning for Ultimate Efficiency
Traditional cell line generation is a grueling process: polyclonal pool screening → positive monoclonal screening → monoclonal expansion. This typically takes 10-14 weeks and suffers from dominant clone bias, which compromises the representativeness of the final cell line.
EDITGENE has developed a disruptive Single-Cell Gene Editing Platform that deeply integrates single-cell dispensing, single-cell culturing, and gene editing. Utilizing the cutting-edge German Cytena UP.SIGHT system, single cells are precisely deposited into 96-well plates. Combined with our proprietary CFM cloning supplement (which drastically boosts cloning efficiency) and Flash-KO in-situ editing, researchers can obtain single-cell-derived edited lines in one step. This completely bypasses traditional polyclonal screening and shrinks the turnaround time to just 6-8 weeks.
Core Technical Advantages
UP.SIGHT Single-Cell Dispensing: A premium 3D cell-printing system ensuring >99% dispensing accuracy to guarantee true monoclonality.
CFM Cloning Supplement:
A proprietary formulation that promotes single-cell adhesion and proliferation, drastically elevating colony formation rates.
A proprietary formulation that promotes single-cell adhesion and proliferation, drastically elevating colony formation rates.
FLASH Delivery Method:
Performs gene editing directly at the single-cell level without waiting for expansion. Yields a 60-80% success rate for homozygous monoclonal knockouts.
Performs gene editing directly at the single-cell level without waiting for expansion. Yields a 60-80% success rate for homozygous monoclonal knockouts.
Rapid Cycle:
Eliminates the polyclonal screening bottleneck, shortening timelines by 30% (down to 6-8 weeks).
Eliminates the polyclonal screening bottleneck, shortening timelines by 30% (down to 6-8 weeks).
Single-Cell Gene Editing vs. Conventional Workflows: Unmatched Leadership
| Comparison Metric | Conventional Limiting Dilution | Electroporation / Viral Transfection + Selection | Single-Cell Gene Editing Platform |
| Monoclonal Isolation Method | Manual limiting dilution; high randomness; prone to polyclonal contamination | Limiting dilution after polyclonal pool screening; cumbersome steps | UP.SIGHT precision plating; >99% single-cell accuracy |
| Multi-round Screening | Yes (2-3 rounds) | Yes (Antibiotic selection + Limiting dilution) | No: One-step monoclonal acquisition |
| Turnaround Time | 12-20 Weeks | 14-18 Weeks | 8-10 Weeks (30% reduction) |
| Cloning Efficiency | 10-30% (Cell-line dependent) | 10-30% | 31-62% (62.5% for 293T, 31.25% for HeLa) |
| KO Success Rate (Monoclonal) | 30-50% | 40-60% | 60-100% (100% for HeLa, 80% for 293T) |
| Cellular Damage | Low (but requires frequent passaging) | High (Electroporation and selection stress) | Low (In situ transfection; no trypsinization required) |
| Automation Level | Manual; high batch-to-batch variance | Semi-automated | Fully Automated (UP.SIGHT image recognition & dispensing) |
| Applicable Cell Types | Standard adherent cells | Broad | Broad (Covers both adherent and suspension cells) |
Service Types
Standard Services
| Service Type | Technical Solution | Target Scenarios | Deliverables | Turnaround |
| Single Gene KO (Standard) | UP.SIGHT Plating + CFM Supplement + FLASH-RNP | KO in standard adherent/suspension cell lines | Homozygous monoclonal lines (≥2) + Sequencing report + Colony images | 8-10 Weeks |
| Multi-gene Co-knockout | Simultaneous delivery of multiple sgRNAs + Single-cell screening | Double/Triple gene combined KO (e.g., immune checkpoint combinations) | Homozygous multi-KO monoclonal lines + Validation report | 10-12 Weeks |
| High-Throughput Arrayed KO | 96-well pre-designed sgRNA library + Automated plating/transfection | Genome-wide screening, drug target discovery, pathway analysis | Monoclonal cell line per well (pool or clone options) | 12-16 Weeks |
| Point Mutation (Custom) | Single-cell plating + FLASH-PE7 Prime Editing | SNVs, small indels (e.g., disease models) | Homozygous PM monoclonal lines + Sequencing report | 12-16 Weeks |
| Gene Knock-in (Custom) | Single-cell plating + FLASH-KI (RNP+Donor) + NHEJ Inhibitor | Reporter KI, tag insertion, conditional alleles | Homozygous KI monoclonal lines + Sequencing/Flow report | 12-16 Weeks |
Success Cases
-
293T B2M Knockout: Efficient Acquisition of 48 Homozygous Clones
-
Objective: Construct B2M knockout cell lines in 293T cells.Workflow: UP.SIGHT single-cell plating → CFM-promoted cloning → FLASH-KO transfection.Results: Achieving a 62.5% colony formation rate in 96-well plates and an 80% success rate for homozygous KO monoclones. The project cycle was shortened by 2-3 weeks.
A549 & HeLa B2M Knockout: 100% Knockout Success Rate
Workflow: UP.SIGHT single-cell plating → CFM-promoted cloning → FLASH-KO transfection.
Results: Formed 38 and 65 clones in 96-well plates respectively, with a 100% success rate for homozygous KO monoclones. High-quality cell lines were obtained in one step without additional screening.
HAP1 High-Throughput Knockout of 96 Different Genes
Workflow: 96-well single-cell plating → Target-specific FLASH-KO transfection per well.
Results: 70 clones were formed (72.9% efficiency), yielding 42 homozygous KO monoclones (60% success rate). This demonstrates the platform’s high reliability for high-throughput gene editing.
